Proteo, Inc - PTEO

Proteo, Inc., a clinical stage drug development company, intends to develop, promote, and market pharmaceuticals and other biotech products in the United States. The company focuses on the development of anti-inflammatory treatments for rare diseases. Its proprietary product includes Elafin, a human protein that naturally occurs in human skin, lungs, and mammary glands. The company’s product is intended for the treatment of post-surgery damage to tissue, pulmonary hypertension, serious injuries caused by accidents, cardiac infarction, and other diseases, as well as for the complications resulting from organ transplantation. Proteo, Inc. has a license and collaboration agreement with ARTES Biotechnology GmbH to produce Elafin by using the sublicensed yeast HANSENULA POLYMORPHA. The company was founded in 1992 and is based in Irvine, California.